Corvus

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

Retrieved on: 
Wednesday, March 13, 2024
Webcast, Corvus

BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 19, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2023 financial results.

Key Points: 
  • BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 19, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2023 financial results.
  • The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or by clicking on this link for instant telephone access to the event.
  • The live webcast may be accessed via the investor relations section of the Corvus website.
  • A replay of the webcast will be available on Corvus’ website for 90 days.

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Allergy, Neoplasm, FDA, Research, Psoriasis, Kidney cancer, NSCLC, Scientific Reports, Carcinoma, Pulmonary fibrosis, Nivolumab, Asilomar International Conference on Climate Intervention Technologies, T helper cell, Preprint, Scleroderma, PTCL, Pembrolizumab, Head, 65th Infantry Regiment, BioRxiv, Cytokine, Time management, Ipilimumab, RCC, ITK, Society, ASH, Clinical trial, Science, Asthma, Cancer, Webcast, Lung cancer, Autoimmunity, Total, Conference call, Patient, Lymphoma, Communications satellite, Pharmaceutical industry, Vaccine, Cryptocurrency, T helper 17 cell, Corvus, Conference

BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • The paper highlights the potential of selective ITK inhibition for the treatment of cancers and helps to confirm preclinical and clinical results generated by Corvus.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the third quarter 2023 financial results.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

Retrieved on: 
Tuesday, October 31, 2023
Webcast, Corvus, Fine chemical, Mobile phone

BURLINGAME, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results.

Key Points: 
  • BURLINGAME, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results.
  • The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or by clicking on this link for instant telephone access to the event.
  • The live webcast may be accessed via the investor relations section of the Corvus website.
  • A replay of the webcast will be available on Corvus’ website for 90 days.

Travelers to Acquire Corvus Insurance

Retrieved on: 
Friday, November 3, 2023
Software, Insurance, Networks, Artificial Intelligence, Data Management, Professional Services, Technology, Apps, Applications, Slate, Traveler, Policy, NYSE, The Travelers Companies, Jefferies Group, Acquisition, Bond, Skadden, Arps, Slate, Meagher & Flom, LLP, Risk, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, Algorithm, TRV, Investment, Corvus

The Travelers Companies, Inc. (NYSE: TRV ) today announced that it has agreed to acquire Corvus Insurance Holdings, Inc. for approximately $435 million.

Key Points: 
  • The Travelers Companies, Inc. (NYSE: TRV ) today announced that it has agreed to acquire Corvus Insurance Holdings, Inc. for approximately $435 million.
  • Founded in 2017, Corvus is an industry-leading cyber insurance managing general underwriter, powered by proprietary technology.
  • “Corvus’ expertise in excess and surplus lines for cyber, along with our industry-leading distribution position in the admitted markets, is a powerful combination,” said Jeff Klenk, Executive Vice President and President of Bond & Specialty Insurance at Travelers.
  • We have a strong working relationship with the Corvus team through our existing cyber capacity arrangements in the United States and Europe, and we are thrilled to have them join the Travelers family.”
    Madhu Tadikonda, Chief Executive Officer of Corvus, said, “At Corvus we have been building a safer world through cyber insurance products and digital tools that reduce risk and improve resilience for policyholders.

Corvus Insurance Expands Cyber Underwriting Relationship with Travelers

Retrieved on: 
Wednesday, September 20, 2023
Security, Professional Services, Technology, Insurance, Software, Knowledge, Corvus, Traveler

Corvus Insurance , the leading cyber underwriter powered by a proprietary AI-driven cyber risk platform, today announced that it has expanded its relationship with Travelers, a leader in personal, business and specialty insurance.

Key Points: 
  • Corvus Insurance , the leading cyber underwriter powered by a proprietary AI-driven cyber risk platform, today announced that it has expanded its relationship with Travelers, a leader in personal, business and specialty insurance.
  • Beginning Oct. 1, 2023, Travelers will serve as a capacity provider for Corvus products in the United States.
  • “Travelers has an unmatched reputation, extensive knowledge of the cyber insurance market and an intimate understanding of the complexities surrounding the evolving cyber landscape,” said Corvus CEO Madhu Tadikonda.
  • For more information about the new cyber insurance program and how it can benefit your business, please visit corvusinsurance.com .

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

Retrieved on: 
Wednesday, September 6, 2023
PTCL, TCL, ASH, Lymphoma, Progression-free survival, ITK, Clinical trial, Exposition, PT, T-cell lymphoma, Publication, Preprint, Hematological Cancer Research Investment and Education Act, Patient, Clutch (eggs), Webcast, Poster, FDA, Society, Pharmaceutical industry, Vaccine, Corvus, T helper cell

BURLINGAME, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, confirmed today that it completed an End-of-Phase/Pre-Phase 3 meeting with FDA on its plans to initiate a Phase 3 registrational clinical trial of soquelitinib (formerly CPI-818), the Company's ITK inhibitor product candidate, in relapsed peripheral T cell lymphoma (PTCL).

Key Points: 
  • “We are pleased with the outcome of our End-of-Phase/Pre-Phase 3 meeting with FDA, allowing us to advance ITK inhibition with soquelitinib into a potentially registrational clinical trial for patients with relapsed peripheral T cell lymphoma,” said Richard A. Miller, co-founder, president and chief executive officer of Corvus.
  • “We appreciate the FDA’s input and their confirmation on the key aspects of the trial design, including sample size, dosing, eligibility, comparator arm and endpoints.
  • We are now focused on finalizing the study protocol, qualifying trial sites and completing other standard steps required to initiate the trial.
  • ET (5:30 a.m. PT), to discuss the soquelitinib Phase 3 clinical trial plan and other business updates.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Call, Total, TCL, PRS, ALC, BioRxiv, RCC, Neoplasm, KCRC, ITK, Lymphoma, Clinical trial, Extranodal NK/T-cell lymphoma, nasal type, Head, ICB, NSCLC, Cell, Lung cancer, Time management, Preprint, Colon, ATM, American Association for Cancer Research, International Conference on Afghanistan, London (2010), Japanese Cancer Association, Patient, Ipilimumab, Melanoma, Blood, Cancer, Kidney cancer, CR, Webcast, Research, FDA, Pembrolizumab, PR, Safety, Nivolumab, Communications satellite, Pharmaceutical industry, Cryptocurrency, Corvus, Conference

BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • Based on its current plans, Corvus expects its cash to fund operations into the second half of 2024.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the second quarter 2023 financial results.

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

Retrieved on: 
Tuesday, August 1, 2023
Webcast, Corvus, Fine chemical, Mobile phone

BURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results.

Key Points: 
  • BURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results.
  • The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) or by clicking on this link for instant telephone access to the event.
  • The live webcast may be accessed via the investor relations section of the Corvus website.
  • A replay of the webcast will be available on Corvus’ website for 90 days.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

Retrieved on: 
Thursday, July 6, 2023
Ohio State University, RLK, TCL, University, Stanford University, Neoplasm, ITK, Cancer, T-cell lymphoma, Cell, Publication, Cytotoxic T cell, Immunotherapy, Preprint, Colon, Interleukin, Patient, Melanoma, Peking University, Cytokine, FDA, Autoimmunity, Pharmaceutical industry, Vaccine, Corvus

BURLINGAME, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data on soquelitinib (formerly known as CPI-818), the Company’s ITK inhibitor product candidate, which highlighted the selective inhibition of ITK to potentially enhance anti-tumor immune response to hematologic and solid tumors and provide a novel approach to cancer immunotherapy.

Key Points: 
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • “This significant scientific report demonstrates the potential of highly selective ITK inhibition, now enabled by soquelitinib.
  • The findings reported indicate that ITK is a novel drug target and its blockade may enhance the body’s immune response to cancer.
  • Led to in vivo anti-tumor activity in several mouse tumor models, including colon, renal, melanoma, B cell and T cell tumors.